MedAxiom partners with Shockwave Medical to support ‘game-changing’ IVL technology
MedAxiom, an American College of Cardiology (ACC) company, has announced a new industry partnership with Shockwave Medical designed to educate cardiologists and cardiology programs about the benefits of intravascular lithotripsy (IVL).
Shockwave Medical, now a part of Johnson & Johnson MedTech after being acquired for $13 billion, started developing IVL in 2009. The technology was designed to break up severely calcified plaques in the coronary and peripheral arteries using powerful ultrasonic pulses, clearing the way for cardiologists before percutaneous coronary intervention (PCI). It has now been approved by the U.S. Food and Drug Administration (FDA) to treat both severely calcified peripheral arterial disease and coronary artery disease. A recent study published in JACC: Cardiovascular Interventions found that IVL is linked to considerable improvements in PCI outcomes.
MedAxiom, meanwhile, is a cardiovascular services and consulting firm acquired by the ACC in 2019. MedAxiom specializes in the business side of cardiology, helping guide heart teams through a healthcare environment that can be complex and challenging.
“MedAxiom is thrilled to welcome Shockwave Medical to the community. We strive to connect MedAxiom members with innovators in industry who offer safe and reliable solutions to challenges, and Shockwave Medical is a great example of this with their IVL technology,” Joe Sasson, PhD, MedAxiom’s executive vice president of ventures and chief commercial officer, said in a statement. “We have been following the Shockwave journey from inception, and this game-changing technology brings an important dimension to cardiovascular care for patients with calcified coronary and peripheral arterial disease. MedAxiom is looking forward to supporting Shockwave in its efforts to improve cardiovascular outcomes for patients.”
Other industry partners listed on the MedAxiom website include Medtronic, Edwards, PaceMate, Cardiovascular Associates of America and CVRx. MedAxiom also partners with industry groups outside of the ACC, including the American Society of Nuclear Cardiology and Society for Cardiovascular Angiography and Interventions.
Michael has more than 18 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.